At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
rituximabdrug
Likely dose
rituximab 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis
In Brief
A Phase 2 clinical trial evaluating rituximab for Fibrillary Glomerulonephritis. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibrillary Glomerulonephritis
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartNov 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedJul 23, 2014
Enrollment StartNov 1, 2014
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.9 years ago
Interventions
rituximabdrug
1000 mg infusion